BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 16281071)

  • 21. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
    Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
    Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
    Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
    Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease in acute myeloid leukaemia.
    Liu Yin JA
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of flow cytometric minimal residual disease assessment after the first induction course in Chinese childhood acute myeloid leukemia.
    Xu XJ; Feng JH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
    Leuk Res; 2013 Feb; 37(2):134-8. PubMed ID: 23199895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
    Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
    Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
    Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
    Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The significance of minimal residual disease in patients with t(15;17).
    Grimwade D
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):137-58. PubMed ID: 11987921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
    Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
    Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely.
    Martinelli G; Buonamici S; Visani G; Malagola M; Piccaluga PP; Isidori A; Bosi C; Bonifazi F; Soverini S; Terragna C; Amabile M; Giannini B; Baccarani M
    Leukemia; 2003 Mar; 17(3):650-1; author reply 651-2. PubMed ID: 12646962
    [No Abstract]   [Full Text] [Related]  

  • 31. Quantitative RT-PCR analysis of the MOZ-CBP fusion transcript in therapy-related acute myeloid leukemia with t(8;16)(p11;p13).
    Fujiki A; Imamura T; Furutani A; Hatano W; Asai D; Hirashima Y; Miyachi M; Tamura S; Tsuchiya K; Iehara T; Ishida H; Yoshihara T; Hosoi H
    J Pediatr Hematol Oncol; 2012 Jul; 34(5):402-5. PubMed ID: 22278196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBFbeta/MYH11 transcript.
    Martinelli G; Ottaviani E; Testoni N; Montefusco V; Pastano R; Tura S
    Haematologica; 2000 May; 85(5):552-5. PubMed ID: 10800179
    [No Abstract]   [Full Text] [Related]  

  • 33. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients.
    Mancini M; Cedrone M; Diverio D; Emanuel B; Stul M; Vranckx H; Brama M; De Cuia MR; Nanni M; Fazi F; Mecucci C; Alimena G; Hagemeijer A
    Leukemia; 2000 Mar; 14(3):364-8. PubMed ID: 10720127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
    Weisser M; Kern W; Rauhut S; Schoch C; Hiddemann W; Haferlach T; Schnittger S
    Leukemia; 2005 Aug; 19(8):1416-23. PubMed ID: 15920493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
    Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
    Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
    Venditti A; Maurillo L; Buccisano F; Del Poeta G; Mazzone C; Tamburini A; Del Principe MI; Consalvo MI; De Fabritiis P; Cudillo L; Picardi A; Franchi A; Lo-Coco F; Amadori S
    Leukemia; 2003 Nov; 17(11):2178-82. PubMed ID: 14576731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
    Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
    Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.